News articles about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Argos Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.6104858668408 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Separately, Zacks Investment Research raised Argos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating and three have given a hold rating to the company’s stock. Argos Therapeutics has an average rating of “Hold” and an average target price of $3.23.

Shares of Argos Therapeutics (NASDAQ:ARGS) traded up 6.486% during midday trading on Wednesday, reaching $0.197. The company’s stock had a trading volume of 8,016,407 shares. Argos Therapeutics has a 52 week low of $0.17 and a 52 week high of $5.68. The stock’s market capitalization is $10.83 million. The company has a 50 day moving average of $0.21 and a 200-day moving average of $0.43.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. Equities research analysts predict that Argos Therapeutics will post ($1.19) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/argos-therapeutics-args-getting-somewhat-favorable-press-coverage-analysis-finds/1575887.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.